Akzo to Sell Biomaterials Technology to Ashland

In a transaction set to close in the third quarter of this year, AkzoNobel has announced plans to sell its biomaterials technology to Ashland of the US.

The Dutch chemical producer said the business is in its early phase of commercialization, and the divestment plans follow a strategic review that determined it was not a good fit with the company’s portfolio.

The activities are focused on plant-based chemistry used to develop products for various applications, such as high performance beauty technologies.

“This transaction will enable us to focus on our core technology platforms of specialty surfactants and polymers and help reinforce our leadership position in both areas,” Akzo Nobel said.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.